Bone loss in inflammatory disorders

被引:298
作者
Hardy, R. [1 ]
Cooper, M. S. [1 ]
机构
[1] Univ Birmingham, Inst Biomed Res, Sch Clin & Expt Med, Birmingham B15 2TT, W Midlands, England
关键词
11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE-1; GLUCOCORTICOID-INDUCED OSTEOPOROSIS; RECEPTOR-RELATED PROTEIN-5; NECROSIS-FACTOR-ALPHA; VITAMIN-D-RECEPTOR; KAPPA-B LIGAND; RHEUMATOID-ARTHRITIS; MINERAL DENSITY; OSTEOCLAST DIFFERENTIATION; OSTEOPROTEGERIN LIGAND;
D O I
10.1677/JOE-08-0568
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Chronic inflammatory diseases of almost any cause are associated with bone loss. Bone loss is due to direct effects of inflammation, poor nutrition, reduced lean body mass, immobility and the effects of treatments, especially glucocorticoids. These mechanisnis are complex and interrelated but are ultimately mediated through effects oil the bone remodelling cycle. Inflammatory disease call increase bone resorption, decrease bone formation but most commonly impacts on both of these processes resulting in all uncoupling of bone formation from resorption in favour of excess resorption. This review will illustrate these interactions between inflammation and bone metabolism and discuss how these are, and might be, manipulated as therapies for inflammation related bone loss. Journal of Endocrinology (2009) 201, 309-320
引用
收藏
页码:309 / 320
页数:12
相关论文
共 104 条
[71]   Corticosteroid-induced bone loss in men [J].
Pearce, G ;
Tabensky, DA ;
Delmas, PD ;
Baker, HWG ;
Seeman, E .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1998, 83 (03) :801-806
[72]  
Pers JO, 2008, J PERIODONTOL, V79, P1645, DOI [10.1902/jop.2008.070616, 10.1902/jop.2008.070616 ]
[73]   Parathyroid hormone - a bone anabolic and catabolic agent [J].
Poole, KES ;
Reeve, J .
CURRENT OPINION IN PHARMACOLOGY, 2005, 5 (06) :612-617
[74]   Prereceptor regulation of glucocorticoid action by 11β-hydroxysteroid dehydrogenase:: a novel determinant of cell proliferation [J].
Rabbitt, EH ;
Lavery, GG ;
Walker, EA ;
Cooper, MS ;
Stewart, PM ;
Hewison, M .
FASEB JOURNAL, 2002, 16 (01) :36-44
[75]   Rheumatoid cachexia: metabolic abnormalities, mechanisms and interventions [J].
Rall, LC ;
Roubenoff, R .
RHEUMATOLOGY, 2004, 43 (10) :1219-1223
[76]   Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy [J].
Russell, R. G. G. ;
Watts, N. B. ;
Ebetino, F. H. ;
Rogers, M. J. .
OSTEOPOROSIS INTERNATIONAL, 2008, 19 (06) :733-759
[77]   Teriparatide or alendronate in glucocorticoid-induced osteoporosis [J].
Saag, Kenneth G. ;
Shane, Elizabeth ;
Boonen, Steven ;
Marin, Fernando ;
Donley, David W. ;
Taylor, Kathleen A. ;
Dalsky, Gail P. ;
Marcus, Robert .
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (20) :2028-2039
[78]   Anabolic therapy in glucocorticoid-induced osteoporosis [J].
Sambrook, Philip N. .
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (20) :2084-2086
[79]   Corticosteroid osteoporosis: Practical implications of recent trials [J].
Sambrook, PN .
JOURNAL OF BONE AND MINERAL RESEARCH, 2000, 15 (09) :1645-1649
[80]   Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction [J].
Sato, Kojiro ;
Suematsu, Ayako ;
Okamoto, Kazuo ;
Yamaguchi, Akira ;
Morishita, Yasuyuki ;
Kadono, Yuho ;
Tanaka, Sakae ;
Kodama, Tatsuhiko ;
Akira, Shizuo ;
Iwakura, Yoichiro ;
Cua, Daniel J. ;
Takayanagi, Hiroshi .
JOURNAL OF EXPERIMENTAL MEDICINE, 2006, 203 (12) :2673-2682